Completed PHASE4 INTERVENTIONAL 2-arm NCT00288600

Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease

Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants

Sponsor: Instituto Fernandes Figueira

Conditions Erythroblastosis, Fetal Hyperbilirubinemia

Interventions Intravenous Immunoglobulin Normal saline solution

Updated 9 times since 2017 Last updated: Dec 2, 2015 Started: Oct 31, 2006 Primary completion: Jun 30, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Erythroblastosis, Fetal and Hyperbilirubinemia and is currently completed. Instituto Fernandes Figueira leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Instituto Fernandes Figueira
Oswaldo Cruz Foundation

Data source: Oswaldo Cruz Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rio de Janeiro, Brazil